Visit ClinicalTrials.gov
For more information about the Esprit BTK PAS study.
What treatment is being tested in the Esprit BTK PAS?
This is a study to extend the knowledge on Esprit™ BTK resorbable scaffold, a new device recently approved by the FDA for the treatment of CLTI. The device is implanted in the artery immediately after a balloon angioplasty, providing support and preventing the vessel from reclosing. The scaffold releases a drug into the artery over a few months that promotes healing and keeps the artery open. The device is made of a material that dissolves over time and will be gone from your body in about 3 years.
How long is participation in the Esprit BTK PAS?
Patients in this study will have multiple visits over 3 years.
How many study visits will I have to complete?
There is a total of 5 or 6 study visits (5 visits for patients that did not have a wound at the time of their initial visit, 6 for patients that had a wound at the time of their initial visit) over a period of 3 years.
How many participants are being enrolled in the Esprit BTK PAS?
The Esprit BTK PAS will evaluate about 200 patients from around the world.
What are the benefits of participating in a clinical study?
Clinical studies are very important to advancing medicine and can help others lead healthier lives. Some people join a study because the treatments they have tried for their health problem did not work or because there is no treatment available. By being part of a clinical trial, participants may gain access to new treatments before they are widely available. This particular study is gathering more data on a device that has already been approved for commercialization in several countries, including the United States.
How do I know if I’m eligible to participate in this study?
If you have been diagnosed with CLTI and have blocked arteries below-the-knee, you may be eligible for this study. But there are other criteria that must be met for you to participate in the study. Visit the “What is the Esprit BTK Post-Approval Study (PAS)?” page to learn more.
MAT-2411267 v1.0 | CL1026312
The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is indicated for improving luminal diameter in infrapopliteal lesions in patients with chronic limb-threatening ischemia (CLTI) and total scaffolding length up to 170 mm with a reference vessel diameter of ≥ 2.5 mm and ≤ 4.00 mm.
The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is contraindicated for use in:
Potential adverse events include, but are not limited to:
Allergic reaction or hypersensitivity to contrast agent, anesthesia, scaffold materials (poly[L-lactide] [PLLA], poly[D, L-lactide] [PDLLA], platinum, or everolimus), and drug reactions to anticoagulation or antiplatelet drugs
The risks described below include the anticipated adverse events referenced in the contraindications, warnings, and precautions sections of the everolimus labels / SmPCs and / or observed at incidences ≥ 10% in clinical trials with oral everolimus for different indications. Refer to the drug SmPCs and labels for more detailed information and less frequent adverse events.
There may be other potential adverse events that are unforeseen at this time.
MAT-2403616 v1.0
Stay Connected